East Coast Institute for Research, Jacksonville, FL 32223, USA.
J Clin Hypertens (Greenwich). 2011 Dec;13(12):917-24. doi: 10.1111/j.1751-7176.2011.00549.x. Epub 2011 Nov 7.
Blood pressure (BP) characteristics, such as central aortic pressure and arterial stiffness, independently predict cardiovascular events. The effects of pharmacologically dissimilar β-blockers on these properties have not been fully elucidated. Patients with essential hypertension and without significant concomitant cardiovascular disease were randomly assigned to controlled-release carvedilol, force-titrated to 80 mg (n=22), or atenolol, force-titrated to 100 mg (n=19); each was given once daily for 4 weeks. Baseline characteristics were similar. At the end of week 4, atenolol and carvedilol reduced central and brachial systolic and diastolic BP to a similar extent. Central augmentation index was increased in atenolol-treated patients but not carvedilol-treated patients (atenolol 4.47% vs carvedilol -0.68%; P=.04). Mean augmented central aortic pressure increased slightly during atenolol treatment (+1.1 mm Hg) but decreased slightly during carvedilol treatment (-1.1 mm Hg), although the difference in these changes was not statistically significant (P=.23). Pulse pressure amplification was reduced more with atenolol at week 4 (atenolol -10.7% vs carvedilol -1.8%; P=.02). Therefore, we conclude that carvedilol results in more favorable pulse pressure amplification and augmentation index by increasing arterial compliance and reducing the magnitude of wave reflection, respectively, compared with atenolol.
血压(BP)特征,如主动脉压和动脉僵硬度,独立预测心血管事件。药理上不同的β受体阻滞剂对这些特性的影响尚未完全阐明。原发性高血压且无明显伴发心血管疾病的患者被随机分为控释卡维地洛组(n=22)和阿替洛尔组(n=19),两组分别滴定至 80mg 和 100mg 后每天服用一次,共 4 周。基线特征相似。在第 4 周末,阿替洛尔和卡维地洛均能显著降低中心和肱动脉收缩压和舒张压。阿替洛尔组的中心增强指数增加,但卡维地洛组无此变化(阿替洛尔 4.47% vs 卡维地洛-0.68%;P=.04)。阿替洛尔治疗期间平均增强的中心主动脉压略有升高(+1.1mmHg),卡维地洛治疗期间略有降低(-1.1mmHg),但这些变化的差异无统计学意义(P=.23)。阿替洛尔在第 4 周末更能降低脉搏压放大率(阿替洛尔-10.7% vs 卡维地洛-1.8%;P=.02)。因此,我们的结论是,与阿替洛尔相比,卡维地洛通过增加动脉顺应性和降低波反射幅度,分别导致更有利的脉搏压放大率和增强指数。